SERPASIL
LOE ApproachingNDAORALELIXIRPriority Review
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL is an oral elixir small-molecule drug approved in 1955 by Novartis. The specific mechanism of action and therapeutic indications are not currently documented in available data. This legacy product represents a historical pharmaceutical asset now approaching loss of exclusivity.
LOE Approaching
Moderate competitive pressure (30%) signals a stable but contracting market; team size and hiring activity likely minimal as LOE approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SERPASIL offers minimal active career opportunities due to its LOE-approaching lifecycle stage and zero linked job openings. Working on this product would involve managing decline, preparing for generic competition, and supporting organizational transition or divestiture planning.
Brand Manager (generic transition)Commercial Operations Analyst
Worked on SERPASIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.